248 related articles for article (PubMed ID: 36175301)
1. The role of RAS oncogenes in controlling epithelial mechanics.
Nyga A; Ganguli S; Matthews HK; Baum B
Trends Cell Biol; 2023 Jan; 33(1):60-69. PubMed ID: 36175301
[TBL] [Abstract][Full Text] [Related]
2. An Excitable Ras/PI3K/ERK Signaling Network Controls Migration and Oncogenic Transformation in Epithelial Cells.
Zhan H; Bhattacharya S; Cai H; Iglesias PA; Huang CH; Devreotes PN
Dev Cell; 2020 Sep; 54(5):608-623.e5. PubMed ID: 32877650
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells.
Pollock CB; Shirasawa S; Sasazuki T; Kolch W; Dhillon AS
Cancer Res; 2005 Feb; 65(4):1244-50. PubMed ID: 15735008
[TBL] [Abstract][Full Text] [Related]
4. The Importance of Being PI3K in the RAS Signaling Network.
Cuesta C; Arévalo-Alameda C; Castellano E
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356110
[TBL] [Abstract][Full Text] [Related]
5. F-actin dynamics regulates mammalian organ growth and cell fate maintenance.
Pocaterra A; Santinon G; Romani P; Brian I; Dimitracopoulos A; Ghisleni A; Carnicer-Lombarte A; Forcato M; Braghetta P; Montagner M; Galuppini F; Aragona M; Pennelli G; Bicciato S; Gauthier N; Franze K; Dupont S
J Hepatol; 2019 Jul; 71(1):130-142. PubMed ID: 30878582
[TBL] [Abstract][Full Text] [Related]
6. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
Amundadottir LT; Leder P
Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037
[TBL] [Abstract][Full Text] [Related]
7. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.
Oberst MD; Beberman SJ; Zhao L; Yin JJ; Ward Y; Kelly K
BMC Cancer; 2008 Jul; 8():189. PubMed ID: 18597688
[TBL] [Abstract][Full Text] [Related]
8. The impact of oncogenic RAS on redox balance and implications for cancer development.
Lim JKM; Leprivier G
Cell Death Dis; 2019 Dec; 10(12):955. PubMed ID: 31852884
[TBL] [Abstract][Full Text] [Related]
9. SCH 51344 inhibits ras transformation by a novel mechanism.
Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
[TBL] [Abstract][Full Text] [Related]
10. Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells.
Shao J; Evers BM; Sheng H
Cancer Res; 2004 Jan; 64(1):229-35. PubMed ID: 14729629
[TBL] [Abstract][Full Text] [Related]
11. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras.
Vasudevan KM; Burikhanov R; Goswami A; Rangnekar VM
Cancer Res; 2007 Nov; 67(21):10343-50. PubMed ID: 17974977
[TBL] [Abstract][Full Text] [Related]
12. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase.
McFall A; Ulkü A; Lambert QT; Kusa A; Rogers-Graham K; Der CJ
Mol Cell Biol; 2001 Aug; 21(16):5488-99. PubMed ID: 11463831
[TBL] [Abstract][Full Text] [Related]
14. Myosin light chain kinase and acto-myosin contractility modulate activation of the ERK cascade downstream of oncogenic Ras.
Helfman DM; Pawlak G
J Cell Biochem; 2005 Aug; 95(5):1069-80. PubMed ID: 15962288
[TBL] [Abstract][Full Text] [Related]
15. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.
Porter AC; Vaillancourt RR
Oncogene; 1998 Sep; 17(11 Reviews):1343-52. PubMed ID: 9779982
[TBL] [Abstract][Full Text] [Related]
17. In Drosophila, RhoGEF2 cooperates with activated Ras in tumorigenesis through a pathway involving Rho1-Rok-Myosin-II and JNK signalling.
Khoo P; Allan K; Willoughby L; Brumby AM; Richardson HE
Dis Model Mech; 2013 May; 6(3):661-78. PubMed ID: 23324326
[TBL] [Abstract][Full Text] [Related]
18. The Ras signal transduction pathway.
Khosravi-Far R; Der CJ
Cancer Metastasis Rev; 1994 Mar; 13(1):67-89. PubMed ID: 8143346
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
20. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
Lim KH; Counter CM
Cancer Cell; 2005 Nov; 8(5):381-92. PubMed ID: 16286246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
